Skip to main content
main-content
Top

02-04-2020 | FDA | News

approvalsWatch

FDA approves durvalumab combination for extensive-stage SCLC

Author: Lynda Williams

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: Durvalumab has been approved by the US FDA for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) in combination with etoposide and carboplatin or cisplatin.

The PD-L1 inhibitor should be administered at a dose of 1500 mg every 3 weeks immediately before beginning chemotherapy on a 3-week cycle and then every 4 weeks thereafter.

The approval is based on the findings of the CASPIAN open-label trial which demonstrated a significant overall and progression-free survival gain with durvalumab plus chemotherapy versus chemotherapy alone in this patient population, as well as an improvement in patient-reported outcomes.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 

share
SHARE
print
PRINT